Literature DB >> 7541612

Tumor angiogenesis in advanced stage ovarian carcinoma.

H C Hollingsworth1, E C Kohn, S M Steinberg, M L Rothenberg, M J Merino.   

Abstract

Tumor angiogenesis has been found to have prognostic significance in many tumor types for predicting an increased risk of metastasis. We assessed tumor vascularity in 43 cases of advanced stage (International Federation of Gynecologists and Obstetricians stages III and IV) ovarian cancer by using the highly specific endothelial cell marker CD34. Microvessel counts and stage were associated with disease-free survival and with overall survival by Kaplan-Meier analysis. The plots show that higher stage, higher average vessel count at 200x (200x avg) and 400x (400x avg) magnification and highest vessel count at 400x (400x high) magnification confer a worse prognosis for disease-free survival. Average vessel count of less than 16 (400x avg, P2 = 0.01) and less than 45 (200x avg, P2 = 0.026) suggested a better survival. Similarly, a high vessel count of less than 20 (400x high, P2 = 0.019) conferred a better survival as well. The plots suggest that higher stage, higher average vessel count at 200x and 400x, and highest vessel count at 200x and 400x show a trend to worse overall survival as well. With the Cox proportional hazards model, stage was the best predictor of overall survival, however, the average microvessel count at 400x was found to be the best predictor of disease-free survival. These results suggest that analysis of neovascularization in advanced stage ovarian cancer may be a useful prognostic factor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541612      PMCID: PMC1869875     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  INTRATUMORAL VASCULAR CHANGES WITH INCREASED SIZE OF A MAMMARY ADENOCARCINOMA: NEW METHOD AND RESULTS.

Authors:  A W VOGEL
Journal:  J Natl Cancer Inst       Date:  1965-05       Impact factor: 13.506

2.  Principles and methods for the morphometric study of the lung and other organs.

Authors:  E R WEIBEL
Journal:  Lab Invest       Date:  1963-02       Impact factor: 5.662

3.  Angiogenesis and breast cancer.

Authors:  J Folkman
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

4.  Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival.

Authors:  R F Ozols; A J Garvin; J Costa; R M Simon; R C Young
Journal:  Cancer       Date:  1980-02       Impact factor: 6.860

5.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

Review 6.  Tumor angiogenesis.

Authors:  J Folkman
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

7.  Importance of histologic grading in the prognosis of epithelial ovarian carcinoma.

Authors:  B Sorbe; B Frankendal; B Veress
Journal:  Obstet Gynecol       Date:  1982-05       Impact factor: 7.661

8.  Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease.

Authors:  D Olivarez; T Ulbright; W DeRiese; R Foster; T Reister; L Einhorn; G Sledge
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

9.  Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet.

Authors:  P Macchiarini; G Fontanini; E Dulmet; V de Montpreville; A R Chapelier; J Cerrina; F L Ladurie; P G Dartevelle
Journal:  Ann Thorac Surg       Date:  1994-06       Impact factor: 4.330

10.  Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study.

Authors:  A Srivastava; P Laidler; L E Hughes; J Woodcock; E J Shedden
Journal:  Eur J Cancer Clin Oncol       Date:  1986-10
View more
  82 in total

1.  Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast.

Authors:  T Hasebe; S Sasaki; S Imoto; A Ochiai
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

Authors:  S John Weroha; Ann L Oberg; Katie L Allen Ziegler; Shaker R Dakhilm; Kendrith M Rowland; Lynn C Hartmann; Dennis F Moore; Gary L Keeney; Prema P Peethambaram; Paul Haluska
Journal:  Gynecol Oncol       Date:  2011-04-22       Impact factor: 5.482

4.  Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Authors:  Jason A Konner; Diana M Grabon; Scott R Gerst; Alexia Iasonos; Howard Thaler; Sandra D Pezzulli; Paul J Sabbatini; Katherine M Bell-McGuinn; William P Tew; Martee L Hensley; David R Spriggs; Carol A Aghajanian
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

5.  Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.

Authors:  José Augusto Rinck-Junior; Cristiane Oliveira; Gustavo Jacob Lourenço; Regina Aparecida Martinho Sagarra; Sophie Françoise Mauricette Derchain; José Getulio Segalla; Carmen Silvia Passos Lima
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-05       Impact factor: 4.553

6.  Significance of angiogenesis and microvascular invasion in renal cell carcinoma.

Authors:  Yoram Dekel; Rumelia Koren; Valentina Kugel; Pinhas M Livne; Rivka Gal
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

7.  Clotrimazole is an inhibitor of inflammatory angiogenesis and the metabolic activity in sponge granuloma.

Authors:  M da Rocha e Silva; A V Belo; R D Machado; S P Andrade
Journal:  Inflammation       Date:  1998-12       Impact factor: 4.092

Review 8.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

9.  Bevacizumab and ovarian cancer.

Authors:  Agustin Garcia; Harpreet Singh
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

10.  Study on tumor angiogenesis in epithelial ovarian carcinoma.

Authors:  Z Wang; H Wang; M Lin
Journal:  J Tongji Med Univ       Date:  2000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.